AMEX:VNRX

VolitionRx Limited Announces Second Quarter 2020 Financial Results and Business Update

AUSTIN, Texas, August 13, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the second quarter endedJune 30, 2020. Volition management will host a conference call tomorrow,August 14 at 8:30 a.m. U.S. Eastern Time...

2020-08-14 04:10 2554

VolitionRx Limited Schedules Second Quarter 2020 Earnings Conference Call and Business Update

AUSTIN, Texas, Aug. 10, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call onFriday, August 14, at 8:30 a.m. Eastern time to discuss its financial and operating results for the second quarter 2020, in addition to providing a b...

2020-08-10 19:30 7012

Volition Announces Promising Clinical Trials Results for its Novel COVID-19 Triage Test

AUSTIN, Texas, July 14, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company applying its Nu.Q™ Nucleosomics™ technology to develop simple, cost effective blood-based tests for cancer and other diseases, today announced that results from...

2020-07-14 18:00 15459

VolitionRx Releases Business Update Video and Announces Addition to the Russell 3000® and Russell Microcap® Indexes

AUSTIN, Texas, June 25, 2020 /PRNewswire/ -- VolitionRx Limited  (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost-effective blood tests to help diagnose a range of cancers and other diseases, today released ...

2020-06-25 20:45 11003

Volition Announces Cameron Reynolds, President and Chief Executive Officer Invited as Presenter at Maxim's COVID-19 Virtual Conference

AUSTIN, May 27, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that President and Chief Executive Officer,Cameron Reynolds has been invited to present at The Role of Cell Therapy and Clarity on Testing Conference organised by the Maxim Group. Event Det...

2020-05-27 20:45 9187

VolitionRx Announces Closing of $13.8 Million Public Offering of Common Stock

AUSTIN, Texas, May 22, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company that applies its NucleosomicsTM platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to hel...

2020-05-23 04:01 10461

VolitionRx Announces Pricing of Underwritten Public Offering of Common Stock

AUSTIN, Texas, May 20, 2020 /PRNewswire/ -- VolitionRx Limited  (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company that applies its NucleosomicsTM platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to hel...

2020-05-20 20:45 10103

VolitionRx Announces Proposed Underwritten Public Offering of Common Stock

AUSTIN, Texas, May 19, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to help diagnose a range of cancers a...

2020-05-20 04:01 7816

VolitionRx To Present First Data on Nu.Q™ Capture Performance and Nu.Q™ Assay Performance in Lung Cancer and Blood Cancer at the 2020 ASCO Annual Meeting

AUSTIN, Texas, May 13, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), an epigenetics company developing simple, easy to use and cost effective blood tests to help diagnose a range of cancers, will present three abstracts at the 2020 ASCO Annual Meeting. The first abs...

2020-05-14 06:54 7336

VolitionRx Limited Announces First Quarter 2020 Financial Results and Business Update

AUSTIN, Texas, May 7, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the first quarter endedMarch 31, 2020. Volition management will host a conference call tomorrow,May 8 at 8:30 a.m. U.S. Eastern Time to disc...

2020-05-08 04:10 9358

VolitionRx Limited Schedules First Quarter 2020 Earnings Conference Call and Business Update

AUSTIN, Texas, May 5, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call onFriday, May 8, at 8:30 a.m. Eastern time to discuss its financial and operating results for the first quarter 2020, in addition to providing a business...

2020-05-05 20:30 7803

Volition's Nu.Q™ Vet Assay Detects Two Common Canine Cancers

AUSTIN, Texas, April 29, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced results from its first proof of concept study conducted byTexas A&M University ("TAMU"). At a specificity of 90%, a single Nu.Q™ Vet assay detected almost 70% of both Canine Hemang...

2020-04-29 20:30 7729

Volition Files Patent for Nu.Q(TM) COVID-19 Triage Test and Commences Proof of Concept Studies

AUSTIN, Texas, April 23, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it is actively developing a COVID-19 triage test aiming to predict the likelihood that an individual who is COVID-19 positive will develop complications and severe disease, usi...

2020-04-23 20:30 5967

VolitionRx Limited Releases Annual Corporate Brochure and Video

AUSTIN, Texas, March 10, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today issued aCorporate Brochure and new Corporate Video detailing the company's mission, strategy, technology, recent...

2020-03-10 20:45 7043

VolitionRx Limited to Present at Conferences in March 2020

AUSTIN, Texas, Mar. 3, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that its Executive Vice President, Investor Relations,Scott Powell, is scheduled to present at five conferences in March 2020. During the conferences, Dr. Powell will outline Volitio...

2020-03-03 21:30 6844

VolitionRx Limited Announces Full Fiscal Year 2019 Financial Results and Business Update

AUSTIN, Texas, Feb. 20, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the full fiscal year endedDecember 31, 2019. Volition management will host a conference call tomorrow,February 21, at 8:30 a.m. U.S. Easte...

2020-02-21 05:10 9363

VolitionRx Limited Schedules Full Year 2019 Earnings Conference Call and Business Update

AUSTIN, Texas, Feb. 18, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call onFriday, February 21 at 8:30 a.m. Eastern time to discuss its financial and operating results for the fourth quarter and full year 2019, in conjunctio...

2020-02-19 05:10 9442

Volition Unveils Its Epigenetic Toolbox

AUSTIN, Texas, Feb. 18, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that research on its Nu.Q(TM) Capture program has led to the development of a suite of novel epigenetic tools building on the breakthroughs announced last month on its assay platform...

2020-02-18 21:30 7815

VolitionRx Announces Filing of Registration Statements

AUSTIN, Texas, Feb. 7, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has filed registration statements on Form S-3 and Form S-8, respectively, with the Securities and Exchange Commission. The primary purpose of filing the registration statemen...

2020-02-08 06:30 9937

Volition Develops a New Improved Nu.Q™ Assay Format

AUSTIN, Texas, Jan. 13, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today provided an update on its Nu Q™ Clinical Assays which use a magnetic particle-based assay format. Volition has completely re-engineered its Nu.Q™ assays leading to a step-change improvement in...

2020-01-13 22:00 15161
12345